SCHEMBL25979094

SCHEMBL25979094

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc4c(c3)oc3ccc(-c5ccc(N(c6ccccc6)c6ccc7oc8ccccc8c7c6)cc5)cc34)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 3/20 0.40
PLA2G4A P47712 3/20 0.40
MMP12 P39900 2/20 0.38
MMP13 P45452 1/20 0.38
HCRTR1 O43613 1/20 0.36
CHEK2 O96017 1/20 0.36
PLA2G10 O15496 1/20 0.36
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 3/20 0.35
HPGD P15428 3/20 0.35
AHR P35869 2/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CASP3 P42574 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26779174 0.99 PLA2G2A (0.38) PLA2G2APLA2G4AMMP12MMP13HCRTR1
SCHEMBL25979704 0.99 MMP12 (0.38) PLA2G2APLA2G4AMMP12MMP13HCRTR1
SCHEMBL25979097 0.98 PLA2G2A (0.40) PLA2G2APLA2G4AMMP12MMP13HCRTR1
SCHEMBL25979410 0.98 MAPT (0.37) PLA2G2APLA2G4AMMP12MMP13HCRTR1
SCHEMBL25979932 0.96 PLA2G2A (0.38) PLA2G2APLA2G4AMMP12MMP13HCRTR1
SCHEMBL25978772 0.96 MAPT (0.38) PLA2G2APLA2G4AMMP12MMP13HCRTR1
SCHEMBL25979407 0.96 L3MBTL1 (0.37) PLA2G2APLA2G4AMMP12MMP13HCRTR1
SCHEMBL25978774 0.95 MAPT (0.37) PLA2G2APLA2G4AMMP12MMP13HCRTR1
SCHEMBL26779206 0.95 MAPT (0.37) PLA2G2APLA2G4AMMP12MMP13HCRTR1
SCHEMBL24574979 0.95 ALDH1A1 (0.35) PLA2G2APLA2G4AMMP12MMP13CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
EP-4227301-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 PLA2G2A 4090/4885PLA2G4A 4219/4885MMP12 4355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.